The potential for targeting the cutaneous endocannabinoid system to treat eczematous dermatoses. The understanding of patient knowledge and utilization of cannabis/cannabis-derived products as treatments for eczema was limited, highlighting both a gap and an opportunity to engage with the eczema community. The National Eczema Association (NEA) advertised an online survey assessing the use, knowledge, and attitudes of a broad range of cannabis product types via social. Of the 76 people who responded to the survey, 69 (90.79%) had eczema and 7 (9.21%) were primary caregivers for someone who had eczema. Respondents used OTC products purchased without a dermatologist’s recommendation (22 [36.07%], n=61) and medical cannabis recommended by a dermatologist the least (2 [3.12%], n=64). All respondents (50 [100%], n=50) supported medical cannabis use, and the majority (47 [94%], n=50) would be comfortable seeing a dermatologist who recommended medical cannabis. Although 94% of respondents (47, n=50) would be interested in learning more about using medical cannabis to treat eczema, the majority (54 [93.10%], n=58) had never discussed this topic with their healthcare provider. 46.67%(28, n=60) of respondents were unsure whether OTC cannabis-derived products were regulated by the FDA. Eczema patients were open to learning about cannabinoids through over-the-counter products. Dermatologists had been prepared to counsel patients on cannabinoid applications in dermatology as consumer interest and the cannabis industry continue to outpace medical research.
